文献速递肝病

肝肾综合征的新进展

New Developments in Hepatorenal Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-06-07

本文综述肝肾综合征(HRS)诊治新进展,指出基于血清肌酐动态变化的诊断标准将HRS 1型视为急性肾损伤的特殊形式,有望更早识别肾功能障碍;治疗仍以血管加压药联合白蛋白为主,肝移植为根治手段,并讨论了同时肝肾移植的评估需求。

要点

  • 基于血清肌酐动态变化的HRS诊断标准将HRS 1型视为急性肾损伤的特殊形式,有望更早识别肾功能障碍。
  • 肾功能生物标志物在区分HRS与肾前性氮质血症及其他肾脏疾病方面效果令人失望。
  • 多项Meta分析证实血管加压药(主要为特利加压素和去甲肾上腺素)联合白蛋白可改善肾功能并逆转HRS 1型。

核心结论

  • 肝肾综合征是失代偿期肝硬化主要并发症之一,无肝移植时可导致死亡。
  • 基于血清肌酐动态变化的HRS诊断标准将HRS 1型视为急性肾损伤的特殊形式,有望更早识别肾功能障碍。
  • 治疗仍以血管加压药联合白蛋白为主,肝移植为根治手段。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 现行GFR估算模型似乎低估肾功能障碍,纳入肾功能生物标志物的Cr-Cystatin C GFR Equation for Cirrhosis似乎能更准确估算实测GFR。
  • 肾功能生物标志物在区分HRS与肾前性氮质血症及其他肾脏疾病方面效果令人失望。
  • 血清代谢组学分析可能是评估肾功能障碍更有力的工具,但其实际临床意义仍不明确。
  • 由于肝硬化肾功能评估困难及HRS诊断标准和应用严格程度不一,HRS确切发病率和患病率未知,但HRS可能比预期更常见。
  • 多项Meta分析证实血管加压药(主要为特利加压素和去甲肾上腺素)在改善肾功能和逆转HRS 1型方面的价值。

关键数值与推荐

  • HRS诊断标准仍包括排除其他原因所致的肾损伤。
  • HRS诊断标准基于血清肌酐的动态系列变化,将HRS 1型视为急性肾损伤的特殊形式。
  • 肾脏替代治疗、经颈静脉肝内门体分流术和人工肝支持系统在改善HRS结局方面作用非常有限。

临床怎么用

  • 治疗仍以血管加压药联合白蛋白为主,旨在逆转内脏血管扩张并改善肾血流。
  • 肝移植仍是HRS的根治性治疗。
  • 在终末期肝病模型时代,同时肝肾移植频率急剧增加,器官分配政策发生变化,更迫切需要预测单纯肝移植后HRS患者自身肾功能恢复情况,以避免不必要的同时肝肾移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatorenal syndrome (HRS) continues to be one of the major complications of decompensated cirrhosis, leading to death in the absence of liver transplantation. Challenges in precisely evaluating renal function in the patient with cirrhosis remain because of the limitations of serum creatinine (Cr) alone in estimating glomerular filtration rate (GFR); current GFR estimating models appear to underestimate renal dysfunction. Newer models incorporating renal biomarkers, such as the Cr-Cystatin C GFR Equation for Cirrhosis appear to estimate measured GFR more accurately. A major change in the diagnostic criteria for HRS based on dynamic serial changes in serum Cr that regard HRS type 1 as a special form of acute kidney injury promises the possibility of earlier identification of renal dysfunction in patients with cirrhosis. The diagnostic criteria of HRS still include the exclusion of other causes of kidney injury. Renal biomarkers have been disappointing in assisting with the differentiation of HRS from prerenal azotemia and other kidney disorders. Serum metabolomic profiling may be a more powerful tool to assess renal dysfunction, although the practical clinical significance of this remains unclear. As a result of the difficulties of assessing renal function in cirrhosis and the varying HRS diagnostic criteria and the rigor with which they are applied, the precise incidence and prevalence of HRS is unknown, but it is likely that HRS occurs more commonly than expected. The pathophysiology of HRS is rooted firmly in the setting of progressive reduction in renal blood flow as a result of portal hypertension and splanchnic vasodilation. Progressive marked renal cortical ischemia in patients with cirrhosis parallels the evolution of diuretic-sensitive ascites to diuretic-refractory ascites and HRS, a recognized continuum of renal dysfunction in cirrhosis. Alterations in nitrous oxide production, both increased and decreased, may play a major role in the pathophysiology of this evolution. The inflammatory cascade, triggered by bacterial translocation and endotoxemia, increasingly recognized as important in the manifestation of acute-on-chronic liver failure, also may play a significant role in the pathophysiology of HRS. The mainstay of treatment remains vasopressor therapy with albumin in an attempt to reverse splanchnic vasodilation and improve renal blood flow. Several meta-analyses have confirmed the value of vasopressors, chiefly terlipressin and noradrenaline, in improving renal function and reversing HRS type 1. Other interventions such as renal replacement therapy, transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Liver transplantation remains the definitive treatment for HRS. The frequency of simultaneous liver-kidney transplantation has increased dramatically in the Model for End-stage Liver Disease era, with changes in organ allocation policies. This has resulted in a more urgent need to predict native kidney recovery from HRS after liver transplantation alone, to avoid unnecessary simultaneous liver-kidney transplantation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2017. PMID: 28602971. doi:10.1016/j.cgh.2017.05.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。